Fabry disease
X-linked lysosomal storage disorder. GLA mutations (Xq22.1) encoding α-GALACTOSIDASE A (α-Gal A) → deficient enzyme → accumulation of GLOBOTRIAOSYLCERAMIDE (Gb3) + lyso-Gb3 (toxic metabolite) in lysosomes throughout body → multi-system disease. **X-LINKED INHERITANCE**: males more severely affected (classic Fabry); females NOT traditional carriers — X-inactivation/lyonization produces clinically significant symptoms in many heterozygotes (asymptomatic to nearly as severe as males). Incidence: ~1/40,000 males classic Fabry; broader phenotype incl. late-onset cardiac variant ~1/3,100. **CLASSIC PHENOTYPE** (males <1% enzyme activity): **CHILDHOOD ONSET 3-10y** — **NEUROPATHIC PAIN** (acroparesthesias = burning hands/feet; FABRY PAIN CRISES triggered by exercise/heat/stress/fever; often DISABLING; **frequently MISDIAGNOSED as growing pains + fibromyalgia + somatization for years**); ANGIOKERATOMAS (dark red-purple skin lesions especially 'bathing trunk' distribution); CORNEA VERTICILLATA (whorl-like corneal opacity diagnostic on slit lamp; also amiodarone/chloroquine differential); HYPOHIDROSIS / anhidrosis (heat intolerance + reduced sweating); chronic diarrhea + abdominal pain (GI dysmotility); proteinuria progressing **PROGRESSIVE KIDNEY DISEASE → ESRD 4th DECADE** (LEADING MORTALITY CAUSE HISTORICALLY pre-ERT); **HYPERTROPHIC CARDIOMYOPATHY** → dilated CM + arrhythmias + heart failure (5th decade); **CRYPTOGENIC STROKE YOUNG AGE** (white matter lesions + small vessel disease); ophthalmologic; psychiatric (depression + anxiety pain-related). **LATE-ONSET/VARIANT PHENOTYPE**: residual enzyme >1%; milder; primarily cardiomyopathy or cryptogenic stroke adulthood; recognized increasingly as cause of unexplained LVH or HFpEF + cryptogenic stroke. Diagnostics: clinical suspicion (childhood neuropathic pain + family history) + α-Gal A enzyme activity plasma/leukocytes (males diagnostic; female levels VARIABLE due to lyonization — may be FALSELY NORMAL); **LYSO-GB3 plasma/urine** highly sensitive biomarker; **GLA GENE SEQUENCING gold standard** especially females. **CASCADE FAMILY SCREENING CRITICAL** once index case identified. Standard of care: multidisciplinary (genetics + nephrology + cardiology + neurology + pain + ophthalmology + dermatology + audiology + psychiatry). **ENZYME REPLACEMENT THERAPY (ERT) STANDARD OF CARE SINCE 2001**: **AGALSIDASE BETA (FABRAZYME, Sanofi/Genzyme) FDA 2003**; EMA 2001; IV Q2wk 1mg/kg; full-length recombinant α-Gal A. **AGALSIDASE ALFA (REPLAGAL, Shire/Takeda) EMA-APPROVED 2001 (NEVER FDA-approved**, manufacturing issues); widely used internationally; IV Q2wk 0.2mg/kg. Both reduce Gb3 + lyso-Gb3; modest clinical benefits; **IRRs (infusion reactions) common; ANTI-DRUG ANTIBODIES ~50% classic males may reduce efficacy**. **MIGALASTAT (GALAFOLD, Amicus Therapeutics) = ORAL PHARMACOLOGICAL CHAPERONE FDA AUG 2018** for AMENABLE GLA MUTATIONS (binds α-Gal A stabilizing properly folded enzyme; only works missense mutations producing some residual properly-conformable enzyme; ~30-50% of patients amenable per Galafold Amenability Table); EMA 2016; oral QOD; less burdensome than IV ERT. **PEGUNIGALSIDASE ALFA (ELFABRIO, Chiesi/Protalix) = PEGylated α-Gal A FDA MAY 2023**; IV Q2wk; longer half-life + reduced immunogenicity than Fabrazyme; BRIDGE + BALANCE trials. Emerging: SUBSTRATE REDUCTION THERAPY (venglustat) in trials; **GENE THERAPY** multiple AAV-based α-Gal A delivery (FLT190 + AVR-RD-01 + ST-920) in trials. PAIN MANAGEMENT essential: anticonvulsants (gabapentin + pregabalin + carbamazepine); avoid triggers (heat + exercise + stress); pain crisis management. National Fabry Disease Foundation US + Fabry International Network + Fabry Disease Foundation + Fabry Registry + national patient organizations international. ESC 2024 expert consensus + Amicus Galafold Amenability Table. **Editorial**: ENZYME REPLACEMENT THERAPIES (FABRAZYME + REPLAGAL + ELFABRIO) are TRUE PEPTIDE/PROTEIN THERAPIES = recombinant enzymes administered as biologics; named explicitly as standard-of-care. MIGALASTAT (Galafold) is small-molecule chaperone (not peptide). Multi-jurisdictional disease (Replagal EMA-only + Fabrazyme/Elfabrio global FDA-approved). Community peptides Tier 3: BPC-157 angiogenic concern + pediatric uncharacterized (classic Fabry pediatric onset); NMN no GLA engagement + pediatric safety + ERT/Galafold titration biomarkers confounded; GH-axis trio IGF-1 cardiac hypertrophy in Fabry CM + renal hemodynamic in nephropathy + tesamorelin label HIV-LD only. Seventy-eighth deliberate non-elevation of community peptides.
What changes during this transition
Fabry disease is an X-linked lysosomal storage disorder caused by mutations in the GLA gene (Xq22.1) encoding α-galactosidase A. Deficient enzyme activity drives accumulation of globotriaosylceramide (Gb3) and its toxic deacylated metabolite lyso-Gb3 in lysosomes throughout the body, producing a multi-system disease. The classic phenotype (males with <1% residual enzyme activity) presents in childhood from ages 3-10 with acroparesthesias and Fabry pain crises (burning episodes in hands and feet triggered by exercise, heat, fever, or stress — frequently misdiagnosed for years as growing pains, fibromyalgia, or somatization), angiokeratomas in a bathing-trunk distribution, cornea verticillata on slit-lamp, hypohidrosis with heat intolerance, GI dysmotility, and progresses through adulthood to proteinuric kidney disease and ESRD (historically the leading cause of death pre-ERT, typically in the 4th decade), hypertrophic cardiomyopathy progressing to heart failure and arrhythmia (typically 5th decade), and cryptogenic stroke at young ages. The late-onset/variant phenotype carries residual enzyme activity and presents in adulthood — increasingly recognized as a cause of unexplained LVH or HFpEF and cryptogenic stroke. Because inheritance is X-linked, males with classic mutations are uniformly affected; heterozygous females are not 'carriers' in the traditional sense — X-inactivation (lyonization) produces a wide severity range from asymptomatic to nearly as affected as males, with complex genetic-counseling implications. Diagnosis combines clinical suspicion and family history with plasma or leukocyte α-Gal A enzyme activity (diagnostic in males; variable and often falsely normal in heterozygous females due to lyonization), plasma and urine lyso-Gb3 as the sensitive biomarker, and GLA gene sequencing as the gold standard — particularly necessary in females. Cascade family screening once an index case is identified is part of standard care. The standard-of-care therapeutics for Fabry include true peptide/protein therapies: AGALSIDASE BETA (Fabrazyme, Sanofi/Genzyme) recombinant α-Gal A administered IV every 2 weeks at 1 mg/kg, FDA-approved 2003 and globally used; AGALSIDASE ALFA (Replagal, Takeda) recombinant α-Gal A IV every 2 weeks at 0.2 mg/kg, EMA-approved 2001 and widely used internationally but never FDA-approved due to historical manufacturing issues — a multi-jurisdictional reality patients on either side of the Atlantic encounter; and PEGUNIGALSIDASE ALFA (Elfabrio, Chiesi/Protalix), the PEGylated next-generation α-Gal A with longer half-life and reduced immunogenicity, FDA-approved May 2023 from the BRIDGE and BALANCE trials. Anti-drug antibodies develop in roughly half of classic males on ERT and can reduce efficacy. MIGALASTAT (Galafold, Amicus Therapeutics) is an oral pharmacological chaperone — a small-molecule (not a peptide) that stabilizes properly-foldable mutant α-Gal A; it works only for amenable missense GLA mutations per the Galafold Amenability Table (roughly 30-50% of patients), is taken every other day, and was FDA-approved August 2018 (EMA 2016). Multiple AAV-based gene therapy programs (FLT190, AVR-RD-01, ST-920) are in trials. Care is genuinely multidisciplinary: metabolic genetics, nephrology with ACE/ARB renal protection progressing to dialysis or transplant, cardiology with rhythm and HF management and ICD or pacemaker as indicated, neurology and pain management with gabapentinoids and trigger avoidance for crises, ophthalmology, dermatology, audiology, and psychiatry for the depression and anxiety that frequently accompany years of disabling neuropathic pain. Patient advocacy includes the National Fabry Disease Foundation (US), Fabry International Network, and national Fabry organizations across multiple jurisdictions; Fabry Registry data and the 2024 ESC expert consensus inform contemporary practice. Editorially: this is a peptide-companion library, and the load-bearing peptide therapies in Fabry are the ERTs and the upcoming gene therapy — not community-sold peptides. BPC-157, NMN, the GH-axis stack, and semaglutide-class drugs have no GLA-engaging mechanism; their substrate entries exist so /ask can answer honestly when users probe, but none are elevated as discovery options for Fabry. Diagnostic delay (historically 15-20 years from first symptom to diagnosis) and the identity-of-disease questions facing heterozygous females are part of what makes this community fragile and the editorial posture deliberate. Seventy-eighth deliberate non-elevation of community peptides.
Important caveat
Fabry disease is managed by multidisciplinary teams centered on metabolic genetics + nephrology + cardiology + neurology + pain management + ophthalmology + dermatology + audiology + psychiatry. **CLASSIC PHENOTYPE CHILDHOOD ONSET 3-10y**: acroparesthesias + Fabry pain crises often disabling + frequently MISDIAGNOSED as growing pains/fibromyalgia/somatization for years; pediatric diagnosis through symptom pattern + family history + enzyme activity + GLA sequencing. **DIAGNOSTIC DELAY HISTORICALLY 15-20 YEARS** from first symptom to diagnosis. **X-LINKED LYONIZATION**: females NOT traditional carriers — clinical severity spectrum asymptomatic to nearly-as-severe-as-males; enzyme activity may be falsely normal in affected females (lyonization); **GLA SEQUENCING IS GOLD STANDARD ESPECIALLY FEMALES**. **CASCADE FAMILY SCREENING CRITICAL**: once index case identified all first-degree relatives need testing; pre-conception PGT options for X-linked transmission. **LYSO-GB3 PLASMA/URINE = HIGHLY SENSITIVE BIOMARKER**; elevated untreated patients especially classic phenotype; tracks ERT/chaperone response. **PROGRESSIVE KIDNEY DISEASE → ESRD 4TH DECADE** historically leading mortality pre-ERT; ACE/ARB renal protection + nephrology monitoring + dialysis + kidney transplant. **HYPERTROPHIC CARDIOMYOPATHY** 5th decade: ACE/ARB + BB + arrhythmia management + pacemaker if AV block + ICD if VT. **CRYPTOGENIC STROKE YOUNG AGE**: white matter lesions + small vessel disease; cerebrovascular surveillance + stroke prevention. **PAIN CRISES**: anticonvulsants (gabapentin + pregabalin + carbamazepine especially); avoid triggers (heat + exercise + stress + fever); psychiatric support for chronic pain + depression. **ENZYME REPLACEMENT THERAPY (ERT) STANDARD OF CARE SINCE 2001**: **FABRAZYME (agalsidase beta, Sanofi/Genzyme) FDA 2003** IV Q2wk 1mg/kg. **REPLAGAL (agalsidase alfa, Takeda) EMA 2001 (NEVER FDA-approved**, historical manufacturing issues — multi-jurisdictional reality patients on either side of the Atlantic encounter); IV Q2wk 0.2mg/kg lower dose. **ELFABRIO (pegunigalsidase alfa, Chiesi/Protalix) FDA MAY 2023** PEGylated next-generation α-Gal A; longer half-life + reduced immunogenicity. **INFUSION REACTIONS (IRRs) COMMON**: premedication may be needed. **ANTI-DRUG ANTIBODIES ~50% CLASSIC MALES** develop anti-agalsidase antibodies → may reduce efficacy; consideration for switching to Elfabrio or migalastat if amenable. **MIGALASTAT (GALAFOLD) FDA AUG 2018** oral pharmacological chaperone for AMENABLE GLA MUTATIONS (~30-50% per Galafold Amenability Table); only works missense mutations producing some residual properly-conformable enzyme; oral QOD; not a peptide (small molecule). **GENE THERAPY IN TRIALS**: FLT190 + AVR-RD-01 + ST-920 AAV programs. **COMMUNITY PEPTIDES Tier 3**: **BPC-157**: pro-angiogenic VEGF concern in Fabry cardiomyopathy + microvascular cerebrovascular disease; pediatric uncharacterized; no GLA engagement. **NMN**: no engagement with lysosomal Gb3 storage; pediatric safety unknowns; doesn't engage NAD+ relevant pathway for Fabry. **GH-AXIS TRIO**: IGF-1 cardiac hypertrophy concern in Fabry hypertrophic CM + IGF-1 renal hemodynamic in nephropathy; tesamorelin Rule 6 non-propagation (HIV-LD label doesn't extend to Fabry). **PREGNANCY**: ERT continued through pregnancy typically (recombinant enzyme low transplacental crossing); coordinate metabolic genetics + MFM + nephrology + cardiology; carriers + female patients counseled on X-linked transmission (50% sons receive mutation; 50% daughters become carriers/affected). **HETEROZYGOUS FEMALE COUNSELING**: complex identity questions + variable severity + reproductive decisions; mental health support common need. **ACCESS BARRIERS**: ERT costs substantial (~$200-300k/year); access advocacy via patient organizations real. **MULTI-JURISDICTIONAL CONSIDERATIONS**: Replagal EMA-only + Fabrazyme/Elfabrio global FDA-approved; patients moving across jurisdictions may encounter different formularies. **NEWBORN SCREENING**: increasingly available in some jurisdictions; controversial (late-onset variant detection + early treatment questions). National Fabry Disease Foundation (US) + Fabry International Network + Fabry Disease Foundation + Fabry Registry + ESC 2024 reference standards. WADA athletes: ERT requires TUE; community GH secretagogues prohibited.
Want this list to grow? The library is editorial — if there’s a peptide you think belongs on this page with documented or mechanistically-clear evidence, send us a note with the citation and we’ll review it under the same evidence-tier discipline as every other entry.